No added benefit of dimethyl fumarate for multiple sclerosis can be determined, as no suitable data are available, neither for a direct nor for an indirect comparison, report researchers. Dimethyl ...

The investigational drug diroximel fumarate (Vumerity, Biogen/Alkermes) showed statistically superior gastrointestinal (GI) tolerability compared with dimethyl fumarate (Tecfidera, Biogen) in patients ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — Women with MS who were exposed to dimethyl fumarate in the first trimester had no unexpected adverse ...

VANCOUVER — Fingolimod (Gilenya, Novartis) was better tolerated than dimethyl fumarate (Tecfidera, Biogen) in a 2-year comparison of the oral multiple sclerosis (MS) drugs. Patients receiving dimethyl ...

Discover comprehensive details about Dimethyl Fumarate, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window INDIANAPOLIS -- ...

Please provide your email address to receive an email when new articles are posted on . Dimethyl fumarate was safe and lowered relapse rates for up to 5 years in Black and Hispanic/Latino patients ...

The Appraisal Committee considered evidence submitted by the manufacturer of dimethyl fumarate and a review of this submission by the Evidence Review Group (ERG). The DEFINE trial was an international ...

The appraisal committee considered evidence submitted by Almirall and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. The ...

BOSTON--(BUSINESS WIRE)--Cycle Pharmaceuticals Limited (Cycle) is pleased to announce that Cycle Vita is now available with BAFIERTAM, expanding its patient support services in MS, following the ...

Dimethyl fumarate (trade name: Tecfidera) has been approved since January 2014 for adults with relapsing remitting multiple sclerosis (RRMS). In an early benefit assessment pursuant to the Act on the ...